Quarter
Charts

Health In Tech, Inc.

HIT

CIK 0002019505 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$8M
↑+53.1% +$3Mvs FY2024 (Q4)
Operating Income
$4M
↑+15.8% +$477Kvs FY2024 (Q4)
Net Income
$4M
↑+17.1% +$511Kvs FY2024 (Q4)
Gross Profit
$4M
↑+8.7% +$331Kvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
50/100
  • Profitability
    0Insufficient data
  • Liquidity
    100Current Ratio 3.13 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    100Asset Turnover 1.72x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +53.1% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Insufficient data

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project HIT's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

8%

Trailing CAGR unavailable; default 8%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$0.93
Total enterprise IV
$54M
Diluted shares
0.06B
Terminal PV
$39M (72% of total)
Year-5 FCF
$5M
YearProjected FCFDiscounted PV
+1$3M$3M
+2$4M$3M
+3$4M$3M
+4$4M$3M
+5$5M$3M
Terminal$63M$39M

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Stock-based comp (TTM)
$2M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$23M
everything owned
Total liabilities
$6M
everything owed
Stockholders' equity
$17M
shareholder claim

Recent performance · 9 quarters

Revenue↑+53.1% +$3M
$8M
Net Income↑+20.2% +$76K
$452K
Free Cash Flow
$451K

Drill down

HIT Sankey

See Health In Tech, Inc.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

HIT Charts

9 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

HIT Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics